Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616798 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
A Phase 2 study of Schizophrenia, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
- 20
- Study locations
NCT00616798: Completed Phase 2 study of Schizophrenia, sponsored by Hoffmann-La Roche.
NCT00616798 is a Phase 2 study of Schizophrenia that has completed, run by Hoffmann-La Roche. The registered enrollment target is 323 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00616798, a Phase 2 study of Schizophrenia, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent negative or d isorganized thought symptoms. After a 4 week run in period on their current anti psychotic treatment, patients will be randomized to receive placebo 10mg, 30mg, or 60mg of RO4917838 once daily, p.o., as add-on therapy. The anticipated time o n study treatment is \<3 months, and the target sample size is 100-500 individual s.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO4917838
- DRUG Standard antipsychotic therapy
Study Locations (20)
Other
- - Vienna
- - Vienna
- - Curitiba
- - Pelotas
- - Rio de Janeiro
- - Salvador
California
- - Granada Hills
- - Los Angeles
- - Oceanside
- - Torrance
Texas
- - Austin
- - Austin
- - DeSoto
- - Irving
Georgia
- - Atlanta
Illinois
- - Hoffman Estates
New York
- - Brooklyn
Ohio
- - Cincinnati
Oklahoma
- - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00616798 record still lists
NCT00616798 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00616798 names 20 study sites across 9 states, led by Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT00616798 about?
NCT00616798 is a clinical study titled "A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.". This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent negative or d isorganized thought symptoms. After a 4 week run in period...
What is the current status of trial NCT00616798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2008-03. Estimated completion is 2010-02.
What conditions does trial NCT00616798 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00616798?
The interventions under investigation include: Placebo (DRUG), RO4917838 (DRUG), Standard antipsychotic therapy (DRUG).
Who is sponsoring clinical trial NCT00616798?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616798 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00616798's enrollment target sits among peer trials
323 53rd of 315 higher than 263 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia